Direct factor Xa inhibitor in the prevention of thromboembolism

• Autorzy: Meretskyi V. , Meretska I. , Pertsovych V.

Warianty tytułu

PL

Bezpośrednie wprowadzenie inhibitoru czynnika Xa w zapobieganiu żylnej choroby zakrzepowo-zatorowej

• Języki publikacji: EN

Abstrakty

EN

Venous thromboembolism is the third most common cause of vascular death after myocardial infarction and stroke, and is associated with considerable morbidity and premature mortality. The incidence of the most serious consequence of venous thromboembolism, fatal pulmonary embolism, ranges from 0.01% to 5% among hospitalised medical patients with multiple risk factors, and is currently considered the commonest avoidable cause of hospital death. Rivaroxaban is a small-molecule factor Xa inhibitor that belongs to a new class of direct oral anticoagulant agents that directly inhibit single enzymes in the coagulation pathway. Rivaroxaban has many advantages over vitamin K antagonists and unfractionated heparin and may become an alternative to traditional anticoagulant agents in patients at risk for thromboembolism. Moreover, antidotes exist and are in the progress of development, both specific and non-specific, for the treatment of overdose or side effects, including bleeding.

PL

Żylna choroba zakrzepowo-zatorowa jest trzecią najczęstszą przyczyną śmierci naczyniowej tuż po zawale mięśnia sercowego i udarze mózgu, związana jest także z dużą zachorowalnością i przedwczesną umieralnością. Najpoważniejsze konsekwencje żylnej choroby zakrzepowozatorowej oraz śmiertelnej zatorowości płucnej występują w przedziale od 0,01% do 5% wśród hospitalizowanych pacjentów medycznych, u których stwierdzono wiele czynników ryzyka i są obecnie uważane za najczęstszą możliwą do uniknięcia przyczynę śmierci szpitalnej. Rivaroxaban jest drobnocząsteczkowym inhibitorem czynnika Xa, który należy do nowych bezpośrednich doustnych środków przeciwzakrzepowych, które bezpośrednio hamują pojedyncze enzymy w szlaku krzepnięcia. Rivaroksaban charakteryzuje się wieloma zaletami w porównaniu z antagonistami witaminy K i niefrakcjonowaną heparyną i może stać się alternatywą dla tradycyjnych leków przeciwzakrzepowych u pacjentów zagrożonych chorobą zakrzepowo-zatorową. Ponadto istnieją antidota (niektóre są w procesie rozwoju), zarówno swoiste, jak i nieswoiste, stosowane w celu leczenia przedawkowania lub działań niepożądanych, w tym krwawienia.

Słowa kluczowe

EN

human disease; risk factor; myocardial infarction risk; Xa inhibitor; prevention; thromboembolism; venous thromboembolism; drug; fibrinolytic agent; rivaroxaban

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2018
• Tom: 12
• Numer: 4
• Opis fizyczny: p.247-254,fig.,ref.

Twórcy

autor

Meretskyi V.

• Ivan Horbachevsky Ternopil State Medical University, Majdan Voli, 1, 46001 Ternopil, Ukraine

autor

Meretska I.

• Ivan Horbachevsky Ternopil State Medical University, Majdan Voli, 1, 46001 Ternopil, Ukraine

autor

Pertsovych V.

• Ivan Horbachevsky Ternopil State Medical University, Majdan Voli, 1, 46001 Ternopil, Ukraine

Bibliografia

• 1. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine. 2017; 376 (13): 1211-22. https://doi.org/10.1056/NEJMoa1700518
• 2. Jun M, Lix LM, Durand M, Dahl M, Paterson JM, Dormuth CR, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicenter, population based, observational study. BMJ. 2017; 359: j4323. https://doi.org/10.1136/bmj.j4323
• 3. Franchini M, Mannucci PM. Direct oral anticoagulants and venous thromboembolism. European Respiratory Review. 2016; 25: 295-302. https://doi.org/10.1183/16000617.0025-2016
• 4. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016; 149: 315-52. https://doi.org/10.1016/j.chest.2015.11.026
• 5. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Thromb Res. 2014; 134: 931-8. https://doi.org/10.1016/j.thromres.2014.08.014
• 6. Keeling D, Tait RC, Watson H. British Committee of Standards for Haematology. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016; 175(4): 602–13. https://doi.org/10.1111/bjh.14344
• 7. Samama MM, Contant G, E Spiro T, Perzborn E, Le Flem L, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013; 11: 11. https://doi.org/10.1186/1477-9560-11-11
• 8. Lee LH. DOACs – advances and limitations in real world. Thromb J. 2016; 14(Suppl. 1): 17. https://doi.org/10.1186/s12959-016-0111-3
• 9. Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail. 2016; 4(11): 870–80. https://doi.org/10.1016/j.jchf.2016.07.012
• 10. Kubitza D, Berkowitz SD, Misselwitz F. Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications. Clinical and Applied Thrombosis/Hemostasis. 2016; 22(5): 412-22. https://doi.org/10.1177/1076029616631427
• 11. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37(14): 1145–53. https://doi.org/10.1093/eurheartj/ehv466
• 12. Noseworthy PA. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016; 150: 1302. https://doi.org/10.1016/j.chest.2016.07.013
• 13. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee MJ. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. Am Heart Assoc. 2017; 6(7): e005835. https://doi.org/10.1161/JAHA.117.005835
• 14. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010; 30: 376-81. https://doi.org/10.1161/ATVBAHA.110.202978
• 15. Aguiar CCT. Treatment of depression in patients on anticoagulation therapy: antidepressant-rivaroxaban drug interactions. J Drug Metab Toxicol. 2016; 7: 215. https://doi.org/10.4172/2157-7609.1000215
• 16. Muster H, Alcorn JH. Rivaroxaban in chronic hemodialysis patients. Am J Nephrol. 2016; 43: 227-8. https://doi.org/10.1159/000445329
• 17. Olshansky B, Chung MK, Pogwizd SM, Goldschlager N. Arrhythmia essentials (second edition). Philadelphia: Elsevier; 2017.
• 18. Creager MA, Beckman JA, Loscalzo J. Vascular medicine: a companion to Braunwald’s heart disease (second edition). Philadelphia: Elsevier; 2013.
• 19. Price V, Keelig D. Tratment of deep vein thrombosis (DVT) and pulmonary embolism (PE) with rivaroxaban or apixaban in adults. MIL. 2017; 8(1).
• 20. Siegal DM, Konkle BA. What is the effect of rivaroxaban on routine coagulation tests? ASH Education Book. 2014; 1: 334-6. https://doi.org/10.1182/asheducation-2014.1.334
• 21. Sikorska J, Uprichard J. Direct oral anticoagulants: a quick guide. European Cardiology Review. 2017; 12(1): 40–5. https://doi.org/10.15420/ecr.2017:11:2
• 22. Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, Batorova A, Boda Z, Christory F, et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia. 2018; 120(4): 645-56. https://doi.org/10.1016/j.bja.2017.11.082
• 23. Tummala R, Kavtaradze A, Gupta A, Ghosh RK. Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data. International Journal of Cardiology. 2016; 214: 292-8. https://doi.org/10.1016/j.ijcard.2016.03.056
• 24. Grottke O, Levy JH. Prothrombin complex concentrates in trauma and perioperative bleeding. Anesthesiology. 2015; 122: 923–31. https://doi.org/10.1097/ALN.0000000000000608
• 25. Grandhi R, Newman WC, Zhang X, Harrison G, Moran C, Okonkwo D, et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg. 2015; 84: 1956–61. https://doi.org/10.1016/j.wneu.2015.08.042
• 26. Vanden Daelen S, Peetermans M, Vanassche T, Verhamme P, Vandermeulen E. Monitoring and reversal strategies for new oral anticoagulants. Expert Rev Cardiovasc Ther. 2015; 13: 95–103. https://doi.org/10.1586/14779072.2015.987126
• 27. Ragni MV. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders. Hematol Am Soc Hematol Educ Program. 2013; 2013(1): 44-51. https://doi.org/10.1182/asheducation-2013.1.44
• 28. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014; 14: 147–54. https://doi.org/10.1007/s40256-013-0055-y
• 29. Woo JS, Kapadia N, Phanco SE, Lynch CA. Positive outcome after intentional overdose of dabigatran. J Med Toxicol. 2013; 9: 192–5. https://doi.org/10.1007/s13181-012-0276-5
• 30. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-Ch, Hacke W, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2015; 17: 1467–507. https://doi.org/10.1093/europace/euv309
• 31. Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral anticoagulant-associated bleeding. Blood. 2014; 123: 1152–8. https://doi.org/10.1182/blood-2013-09-529784
• 32. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Danbury P, Grosso M, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371: 2141–2. https://doi.org/10.1056/NEJMc1411800

Identyfikatory

DOI

10.5114/hpc.2018.79987